Journal Club VL

Assessing Reader Variability in PSMA-PET/CT Scan Interpretation: A Substudy of the VISION Trial, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen analyze an ad hoc analysis from the VISION study, published in the Journal of Nuclear Medicine. The study investigates the agreement between readers in the interpretation of 68Ga-PSMA-11 PET/CT scans to determine patient eligibility for 177Lu-PSMA-617 Radioligand Therapy in the treatment of prostate cancer. They elaborate on the study's methodology, including the re...

Improving mCRPC Outcomes: VISION Study Highlights Lu-PSMA-617 Impact on Survival and Quality of Life, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen, dissect a publication from the VISION study regarding health-related quality of life and pain outcomes with Lu-PSMA-617+ Standard of Care versus Standard of Care alone in patients with mCRPC. This study, conducted across 84 global centers, reveals that the addition of Lu-PSMA-617 to standard care significantly improved overall survival rates from 11.3 to 15.3 month...

How the TALAPRO-2 Study is Redefining First-line Treatment for Metastatic Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen shed light on the TALAPRO-2 study published in The Lancet. This study evaluated the combination of talazoparib, a potent PARP inhibitor, and enzalutamide in treating men with first-line metastatic castration-resistant prostate cancer (mCRPC). They note the poor prognosis for patients with mCRPC and the need for more effective treatments, especially for those with ho...

Exploring the Role of ATM and BRCA2 Mutations in Metastatic Prostate Cancer Outcomes, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen discuss a publication examining metastatic prostate cancer outcomes in relation to BRCA2 and ATM mutations. Sayyid highlights that around 20-25% of metastatic prostate cancer patients have homologous recombination repair (HRR) gene mutations which are not uniform and can significantly affect treatment responses. He explains that FDA-approved PARP inhibitors (olapari...

Filling the Gap: Creating a Specialized PRO Measure for Radionuclide Therapy in Prostate Cancer, Journal Club - Zachary Klaassen & Rashid Sayyid

Details
Rashid Sayyid and Zach Klaassen a paper on the development of a patient-reported outcomes (PROs) measure for radionuclide therapy for prostate cancer, published in the Journal of Nuclear Medicine. They explain the importance of PROs in evaluating the impact of these emerging oncology treatments on patients' quality of life. Highlighting a current gap in the literature, they note that existing PRO...

Decoding Survival: The Role of Bone Biomarkers in Hormone-Sensitive Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
In this discussion, Rashid Sayyid and Zach Klaassen discuss the findings of a study investigating the significance of bone biomarkers in the prognosis of men with hormone-sensitive prostate cancer. The study, a subgroup analysis from the SWOG S1216 trial, used blood-based biomarkers of bone turnover as prognostic factors for survival. It also examined the performance of Orteronel, a non-steroidal...

The Push for PSMA-PET: Evaluating its Role in Prostate Cancer Diagnosis, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen scrutinize a publication from European Urology comparing the diagnostic accuracy of PSMA PET and traditional imaging modalities in initial staging of intermediate to high-risk prostate cancer. The authors systematically review studies comparing PSMA-PET/CT, MRI, and conventional imaging, noting that PSMA-PET/CT shows higher sensitivity and specificity. They also dis...

The Impact of MDT on Intermittent Hormone Therapy: Insights from the EXTEND Trial, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen dissect the findings of the EXTEND trial, a phase two randomized study focused on the effects of adding metastasis-directed therapy (MDT) to intermittent hormone therapy for oligometastatic prostate cancer. As per the JAMA Oncology published report, despite evidence supporting systemic therapy intensification for metastatic prostate cancer, the combination of MDT an...

Ga-PSMA PET for Evaluation of Response to Chemotherapy for Metastatic Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen analyze a study on the prognostic role of 68 Ga-PSMA-11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy. The researchers note that traditional assessment tools, such as the Prostate Cancer Working Group 3 criteria, often rely on conventional imaging, limiting the ability to differentiate between responders and those with stable di...

Evaluating Outcomes of Enzalutamide and Abiraterone Co-administration: Insights from the ALLIANCE Trial, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen discuss a study on the efficacy of combining enzalutamide and abiraterone in treating metastatic castration-resistant prostate cancer (mCRPC) patients. The study, published in the Journal of Clinical Oncology, posits the potential benefit of using both drugs as they counteract each other's resistance mechanisms. Notably, the drugs have been approved separately by th...